Mesoblast Limited

ABN Newswire Stocks to Watch today include: Mesoblast Limited (ASX:MSB) (PINK:MBLTY), Metallica Minerals Limited (ASX:MLM), Atlas Iron Limited, Warwick Resources Limited (ASX:WRK), AuDAX Resources Limited (ASX:ADX) (PINK:ADXRF), D'Aguilar Gold Limited (ASX:DGR) and Lions Gate Metals Inc (CVE:LGM) (PINK:LGMFF).

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today confirmed that national news items broadcast last Friday on the ABC, Channel 9, Channel 7 and Channel 10 reported on positive preclinical results using its patented adult stem cell technology platform for the treatment of diabetes.

ABN Newswire stocks to watch today include: Stirling Resources (ASX:SRE), Monarch Gold (ASX:MON)(PINK:MARCF), Conquest Mining Limited (ASX:CQT)(PINK:CQMLF), Conquest Mining Limited (ASX:CQT)(PINK:CQMLF) and Fufeng (HKG:0546)(PINK:FFNGY).

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced significant preclinical trial results showing that the proprietary adult stem cell platform could be an effective treatment for diabetes.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) Chairman Brian Jamieson Address At Annual General Meeting.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced today that the first group of patients who received the lowest dose of Revascor(TM), the proprietary "off-the-shelf" adult stem cell product for heart failure, continued to show sustained improvement in heart muscle function at six months.

Mesoblast Limited's (ASX:MSB)(PINK:MBLTY) today announced successful results from the first 18 patients receiving a bone marrow transplant using umbilical cord blood expanded by the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs).

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced that its United States-based associate company, Angioblast Systems Inc., was today featured at the 2009 UBS Global Life Sciences Conference underway in New York.

Mesoblast Limited (ASX:MSB)(PINK:MBLTY) today announced successful completion of enrolment of the second group of 20 patients randomised to receive an increased dose of Revascor(TM), the proprietary allogeneic, or "off-the-shelf", universal adult stem cell product for congestive heart failure.

Mesoblast Limited's (ASX:MSB)(PINK:MBLTY) successful preclinical disc repair trial was featured at the World Congress on Osteoarthritis held in Montreal, Canada, over the weekend. More than 1,000 specialists in orthopaedics and rheumatology, as well as pain doctors and clinical scientists attended the prestigious congress conducted by the OsteoArthritis Research Society International (OARSI).